The Japan Patent Office has awarded Longeveron a patent for its methods used to assess the potency of human mesenchymal stem cells (MSCs). These assay techniques are designed to evaluate the functional properties of MSCs, which are important in various therapeutic applications.
The patented methods provide a standardized approach to measuring the effectiveness and quality of MSCs, supporting their use in clinical and research settings.
**Why this matters**
Potency assays are critical for ensuring the consistency and safety of stem cell therapies. This patent strengthens Longeveron’s intellectual property portfolio and may enhance the development and regulatory approval of MSC-based treatments in Japan and potentially other markets.